CA3212189A1 - Device for treating anaphylaxis - Google Patents

Device for treating anaphylaxis Download PDF

Info

Publication number
CA3212189A1
CA3212189A1 CA3212189A CA3212189A CA3212189A1 CA 3212189 A1 CA3212189 A1 CA 3212189A1 CA 3212189 A CA3212189 A CA 3212189A CA 3212189 A CA3212189 A CA 3212189A CA 3212189 A1 CA3212189 A1 CA 3212189A1
Authority
CA
Canada
Prior art keywords
epinephrine
metered dose
dose inhaler
formulation
pressurized metered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212189A
Other languages
English (en)
French (fr)
Inventor
George Harry LUCIUK
Andrew Robert MARTIN
Conor Aidan RUZYCKI
Warren Hugh Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1232176 BC Ltd
Original Assignee
1232176 BC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1232176 BC Ltd filed Critical 1232176 BC Ltd
Publication of CA3212189A1 publication Critical patent/CA3212189A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/02—Equipment for testing the apparatus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Meat And Fish (AREA)
  • Surgical Instruments (AREA)
  • Non-Portable Lighting Devices Or Systems Thereof (AREA)
CA3212189A 2021-03-23 2022-03-23 Device for treating anaphylaxis Pending CA3212189A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165102P 2021-03-23 2021-03-23
US63/165,102 2021-03-23
PCT/US2022/021612 WO2022204328A1 (en) 2021-03-23 2022-03-23 Device for treating anaphylaxis

Publications (1)

Publication Number Publication Date
CA3212189A1 true CA3212189A1 (en) 2022-09-29

Family

ID=81307871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212189A Pending CA3212189A1 (en) 2021-03-23 2022-03-23 Device for treating anaphylaxis

Country Status (20)

Country Link
US (1) US20220331237A1 (cg-RX-API-DMAC7.html)
EP (2) EP4188332B1 (cg-RX-API-DMAC7.html)
JP (2) JP2024515446A (cg-RX-API-DMAC7.html)
KR (1) KR20230165764A (cg-RX-API-DMAC7.html)
CN (1) CN117083054A (cg-RX-API-DMAC7.html)
AU (1) AU2022245300B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023019156A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212189A1 (cg-RX-API-DMAC7.html)
DK (1) DK4188332T3 (cg-RX-API-DMAC7.html)
ES (2) ES3025005T3 (cg-RX-API-DMAC7.html)
FI (1) FI4188332T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250566T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071185T2 (cg-RX-API-DMAC7.html)
IL (1) IL305534A (cg-RX-API-DMAC7.html)
LT (1) LT4188332T (cg-RX-API-DMAC7.html)
PL (1) PL4188332T3 (cg-RX-API-DMAC7.html)
PT (1) PT4188332T (cg-RX-API-DMAC7.html)
RS (1) RS66787B1 (cg-RX-API-DMAC7.html)
SI (1) SI4188332T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022204328A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514995B2 (en) * 2021-02-15 2026-01-06 Glenmark Pharmaceuticals Limited Metered dose inhalers of fluticasone or an ester thereof
WO2025072756A1 (en) * 2023-09-28 2025-04-03 Kokua Pharma Inc. Device, methods, and uses for treating acute allergic reactions
WO2025170986A1 (en) * 2024-02-06 2025-08-14 Kindeva Drug Delivery L.P. Drug delivery device
US20260007598A1 (en) * 2024-07-05 2026-01-08 Honeywell International Inc. Compositions, devices and methods for respritory delivery of active pharmaceutical ingredients
US12496272B1 (en) * 2024-07-31 2025-12-16 Amphastar Pharmaceuticals, Inc. Stable epinephrine suspension formulation for inhalation with HFO propellant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324250D0 (en) * 1993-11-25 1994-01-12 Minnesota Mining & Mfg Inhaler
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1531794B1 (en) * 2002-06-28 2017-05-10 Civitas Therapeutics, Inc. Inhalable epinephrine
AU2004249166B2 (en) * 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
WO2006101882A2 (en) * 2005-03-16 2006-09-28 Honeywell International Inc. Medicament delivery formulations, devices and methods
US8367734B1 (en) * 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
SI2627386T1 (sl) * 2010-10-12 2015-10-30 Ivax Pharmaceuticals Ireland Nosna pršilna naprava
US20120204871A1 (en) * 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
WO2014033057A1 (en) * 2012-08-29 2014-03-06 Chiesi Farmaceutici S.P.A. Aerosol inhalation device
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US9717683B1 (en) * 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
ES2791775B2 (es) * 2018-02-06 2023-01-20 Aegis Therapeutics Llc Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations

Also Published As

Publication number Publication date
KR20230165764A (ko) 2023-12-05
JP2024515446A (ja) 2024-04-10
EP4188332A1 (en) 2023-06-07
CN117083054A (zh) 2023-11-17
EP4188332B1 (en) 2025-02-12
ES3025005T3 (en) 2025-06-05
RS66787B1 (sr) 2025-06-30
EP4545122C0 (en) 2026-07-15
AU2022245300A1 (en) 2023-09-14
IL305534A (en) 2023-10-01
PL4188332T3 (pl) 2025-11-24
LT4188332T (lt) 2025-05-12
EP4545122A2 (en) 2025-04-30
WO2022204328A1 (en) 2022-09-29
SI4188332T1 (sl) 2025-07-31
FI4188332T3 (fi) 2025-05-06
HUE071185T2 (hu) 2025-08-28
JP2026094267A (ja) 2026-06-09
HRP20250566T1 (hr) 2025-06-20
ES3076082T3 (en) 2026-08-11
EP4545122A3 (en) 2025-05-07
DK4188332T3 (da) 2025-05-05
US20220331237A1 (en) 2022-10-20
PT4188332T (pt) 2025-04-17
BR112023019156A2 (pt) 2023-10-17
AU2022245300B2 (en) 2026-04-02
EP4545122B1 (en) 2026-07-15

Similar Documents

Publication Publication Date Title
EP4188332B1 (en) Device for treating anaphylaxis
AU2003222753B2 (en) Formoterol superfine formulation
US20060018840A1 (en) Aerosolizable formulation comprising nicotine
JP2009537246A (ja) 定量吸入器を用いたトレプロスチニル投与
AU2010258751A1 (en) Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US20210401740A1 (en) Method and system for the treatment of chronic copd with nebulized anticholinergic administrations
HK1221654A1 (zh) 用於呼吸递送三种或更多种活性剂的组合物、方法和系统
EP1415647A1 (en) "Long-acting beta-2 agonists ultrafine formulations"
CA2633099A1 (en) Treatment of respiratory diseases
WO2021033081A1 (en) Stable aerosol composition for inhalation comprising glycopyrronium, formoterol and corticosteroid
JP2004529108A (ja) R−サルメテロールおよびプロピオン酸フルチカゾンを含んでなる医薬製剤
HK40087057A (en) Device for treating anaphylaxis
HK40087057B (en) Device for treating anaphylaxis
WO2025072756A1 (en) Device, methods, and uses for treating acute allergic reactions
HK40102631A (en) Device for treating anaphylaxis
US20100291221A1 (en) Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
CA2872569C (en) Uses of antagonists of hyaluronan signaling
JP2024533453A (ja) 送達デバイスおよび組成物
Hindle Aerosol drug delivery

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240917

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240918

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250314

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250314

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260313

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260323

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20260323

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260323

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION REQUEST RECEIVED

Effective date: 20260323

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260323

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260330

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260330

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260330

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260330

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260330

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260331

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION DETERMINED COMPLIANT

Effective date: 20260408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260408

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260513